Indian CEOs On Plugging Quality Gaps: Yes We Can
This article was originally published in Scrip
Executive Summary
The top bosses of six leading Indian firms were unequivocal that there is room for improvement on the quality front at a recent conference in Mumbai, but they also emphasized senior management engagement and resolve to get a "quality movement" going in their respective firms and in the domestic industry, in general.
You may also be interested in...
Does India's Perpetual Licensing Plan Risk Backfiring?
India's wide-ranging drug regulation overhaul plan, including a perpetual licensing system aimed at simplifying processes and potentially delinking licensing and enforcement responsibilities may well emerge as a double-edged sword.
India's Risk-Based Inspection Plan: Well Begun?
India's Central Drugs Standard Control Organization (CDSCO) is taking definitive steps to strengthen the regulatory regime and enforcement, including across areas such as data integrity, in the backdrop of industry's patchy manufacturing compliance story. The regulator has developed risk-based inspection criteria for manufacturing sites, backed by a comprehensive draft checklist and evaluation tool but the real test may lie in resolute implementation.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.